Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Bazzoli F et al. |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663723
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Sheu BS et al. |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755841
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
Vcev A et al. |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632647
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|